SEC Form 4 · accession 0001306541-18-000003
KYTO BIOPHARMA INC · KBPH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Period of report
Feb 21, 2018
Accepted (ET)
Feb 21, 2018 · 3:32 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001164888
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| CommonF1 | Feb 21, 2018 | J | 958,752 | $1.13 | A | 2,697,085 | D | |
| CommonF2,F3 | Feb 21, 2018 | J | 958,752 | $1.13 | D | 2,697,085 | I | Owner of Comindus Finance Corp. |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This is to report the sale of 958,752 common shares owned by Georges Benarroch to Comindus Finance Corp. and the pledge of 958,752 by Comindus Finance Corp. to Georges Benarroch until such time as the full purchase price has been paid.
- F2-Georges Benarroch, President and Director of the Issuer, is an officer and director of Comindus Finance Corp. and responsible for day to day operations. He is the beneficial owner in securities held by Comindus Finance Corp.
- F3Form 4 Joint Filer Information: Georges Benarroch Address: 78 Hazelton Avenue, Toronto ON M5R2E2 Canada Designated Filer Comindus Finance Corp. Issuer and Ticker Symbol: Kyto BioPharma Inc. (KBPH) Date of Event Requiring Statement: February 21, 2018 Relationship of Reporting Person to Issuer: Director, Officer, President Signature /s/ Georges Benarroch